We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

93 hedge funds and large institutions have $60.4M invested in Summit Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,170% more call options, than puts

Call options by funds: $2.1M | Put options by funds: $165K

55% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 22

0.38% less ownership

Funds ownership: 5.01% → 4.63% (-0.38%)

7% less funds holding

Funds holding: 100 → 93 (-7)

31% less capital invested

Capital invested by funds: $87.7M → $60.4M (-$27.3M)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

Holders
93
Holders Change
-7
Holders Change %
-7%
% of All Funds
1.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
34
Reduced
22
Closed
15
Calls
$2.1M
Puts
$165K
Net Calls
+$1.93M
Net Calls Change
+$1.99M

Top Buyers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
+$1.2M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$530K
3
BlackRock
BlackRock
New York
+$408K
4
Barclays
Barclays
United Kingdom
+$190K
5
JP Morgan Chase
JP Morgan Chase
New York
+$186K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$6.03M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$482K
3
Group One Trading
Group One Trading
Illinois
-$350K
4
Goldman Sachs
Goldman Sachs
New York
-$303K
5
Millennium Management
Millennium Management
New York
-$293K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$199K -$145K -75,800 -42%
UBS Group
27
UBS Group
Switzerland
$183K +$86.7K +45,451 +87%
SFI
28
Susquehanna Fundamental Investments
Pennsylvania
$161K – – –
AllianceBernstein
29
AllianceBernstein
Tennessee
$156K +$20.4K +10,686 +15%
Janus Henderson Group
30
Janus Henderson Group
United Kingdom
$144K +$53 +28 +0%
Invesco
31
Invesco
Georgia
$141K +$1.01K +531 +0.7%
H
32
HoyleCohen
California
$139K – – –
Manulife (Manufacturers Life Insurance)
33
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$127K +$40.3K +21,149 +45%
Deutsche Bank
34
Deutsche Bank
Germany
$122K +$22.3K +11,696 +22%
Bank of America
35
Bank of America
North Carolina
$120K +$104K +54,476 +569%
MIM
36
MetLife Investment Management
New Jersey
$118K – – –
ProShare Advisors
37
ProShare Advisors
Maryland
$113K +$860 +451 +0.7%
AIG
38
American International Group
New York
$108K +$3.92K +2,056 +4%
UBS AM
39
UBS AM
Illinois
$108K +$110K +57,800 New
ETC
40
Exchange Traded Concepts
Oklahoma
$105K -$34.5K -18,073 -24%
VEA
41
Virtus ETF Advisers
New York
$94.8K -$9.63K -5,049 -9%
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$91K +$2.4K +1,259 +3%
Mercer Global Advisors
43
Mercer Global Advisors
Colorado
$90K – – –
VOYA Investment Management
44
VOYA Investment Management
Georgia
$86.6K – – –
ASRS
45
Arizona State Retirement System
Arizona
$74.3K +$1.02K +537 +1%
Teacher Retirement System of Texas
46
Teacher Retirement System of Texas
Texas
$74K +$3.41K +1,790 +5%
VW
47
Vance Wealth
California
$73.4K – – –
LCS
48
Levin Capital Strategies
New York
$73.3K – – –
GVAG
49
Great Valley Advisor Group
Delaware
$63.6K – – –
Group One Trading
50
Group One Trading
Illinois
$61.8K -$350K -183,376 -85%
1
2
3 4 5

SMMT Hedge Fund Activity: Q3 2023 in Review

93 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2023, worth a combined $60.4M — down 31% from $87.7M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of SMMT and 8 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 34 added.

The largest buyer was Charles Schwab, adding an estimated $1.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.03M.

  • 93 institutional investors held Summit Therapeutics (SMMT) as of Q3 2023, down from 100 in Q2 2023.
  • Funds reported $60.4M of Summit Therapeutics stock for Q3 2023, down 31% quarter-over-quarter.
  • 8 funds opened new Summit Therapeutics positions in Q3 2023 and 15 closed out, a net change of -7 holders.
  • The largest Summit Therapeutics buyer in Q3 2023 was Charles Schwab, an estimated $1.2M added.
  • The largest Summit Therapeutics seller in Q3 2023 was Baker Bros. Advisors, an estimated $6.03M sold.

Based on aggregated 13F filings for Q3 2023.